Waystar Considers Sale Amid Decline in Market Value, Sources Reveal

Waystar, a healthcare software provider known for its technology that automates administrative tasks for hospitals and doctors, is reportedly exploring strategic options, including a potential sale. This development comes just two years after the company's public listing in New York. According to seven insiders, the Lehi, Utah, and Louisville, Kentucky-based firm has engaged investment bank Evercore to guide the process, which remains in its initial stages.

Sources have cautioned that these plans could change, and there is no guarantee that a sale will occur. Both Waystar and Evercore have declined to comment on the matter.

Market Valuation Pressures

Waystar's market valuation has taken a hit, plummeting to approximately $4.8 billion following a 24% decrease in its share price this year. This decline aligns with a broader downturn in the software sector. The potential sale process may serve as a barometer for investor interest in software companies amid these challenging market conditions.

Waystar has strategically positioned itself as a technology company, emphasizing its software solutions over traditional healthcare services. This approach initially garnered favorable investor sentiment, propelling its shares from $20 to a peak of $45 in 2025. However, concerns about artificial intelligence disrupting the software industry have since placed downward pressure on the stock, as noted by Morgan Stanley analysts in a July report.

Company Background and Ownership

Established in 2017 through the merger of healthcare revenue management firms Zirmed and Navicure, Waystar was publicly listed in 2024. The company's major stakeholders include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital, with EQT holding the largest share at 13%. CPPIB and BlackRock Institutional Trust Company own 10% and 8% stakes, respectively, according to LSEG data.

When approached for comments, EQT and BlackRock declined, while CPPIB did not immediately respond.

Potential Implications for the Software Sector

The exploration of a sale by Waystar could have broader implications for the software industry, particularly in the healthcare segment. As companies face increasing pressure from market fluctuations and technological advancements, strategic maneuvers such as sales or mergers may become more prevalent.

Waystar's current situation will be closely monitored by industry analysts and investors alike, as it may signal shifting dynamics in the valuation and operation of healthcare technology firms.